Drugs / SYNSORB Pk
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00004465 | Jul 1997 → Apr 2001 | Shiga toxin-associated hemolytic uremic syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYNSORB Pk | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004465 ↗ |
| Modality | Other / unclassified | “a silicon dioxide-based agent” PMID 40277027 ↗ Apr 2025 |
| Route | Oral | “Patients receive oral SYNSORB Pk or placebo three times daily for 7 days” NCT00004465 ↗ |